GlassScriptPhysician profile
Victor Nguyen
NPI 1144330051
$8,638.76
in general payments reported to CMS, 2019-2025
59 companies · $1,355 in 2025
The $1,355 reported for 2025 was more than what 89% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $974 · 2020: $696 · 2021: $1,056 · 2022: $1,268 · 2023: $1,717 · 2024: $1,573 · 2025: $1,355.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,644.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,644.49 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,369.55 | 2019-2025 | |
| Novo Nordisk INC | $835.30 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Glaxosmithkline, LLC. | $603.92 | 2019-2025 | Arexvy, Trelegy Ellipta, Nucala |
| Lilly USA, LLC | $513.78 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $500.80 | 2019-2025 | Airsupra, Breztri, Farxiga |
| Amgen INC. | $486.53 | 2019-2025 | Repatha, Otezla, Evenity |
| Antares Pharma, INC. | $330.44 | 2022-2025 | Xyosted, Tlando, Nocdurna |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $321.62 | 2019-2025 | Xifaxan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $268.73 | 2019-2025 | Jardiance, Tradjenta |
| Novartis Pharmaceuticals Corporation | $250.47 | 2019-2024 | |
| Pfizer INC. | $241.69 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $223.16 | 2019-2023 | Xarelto |
| Bayer Healthcare Pharmaceuticals INC. | $196.30 | 2022-2025 | |
| Allergan, INC. | $189.13 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $186.96 | 2019-2024 |
Show all 59 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $167.54 | 2024-2025 | |
| Otsuka America Pharmaceutical, INC. | $153.61 | 2023-2024 | Rexulti, Nuedexta |
| Abbott Laboratories | $141.56 | 2019-2025 | Freestyle Libre 3 |
| Silk Road Medical, INC. | $132.75 | 2023 | Enroute Transcarotid Stent, Enroute Transcarotid Neuroprotection System |
| Exact Sciences Corporation | $111.32 | 2023-2025 | Cologuard Collection Kit |
| E.R. Squibb & Sons, L.L.C. | $101.73 | 2020-2024 | Eliquis |
| Balt USA, LLC | $93.14 | 2023 | Prestige Coil System |
| Sumitomo Pharma America, INC. | $84.87 | 2023-2025 | Gemtesa |
| Alcon Vision LLC | $78.81 | 2019 | |
| Verity Pharmaceuticals INC. | $75.85 | 2025 | Tlando |
| Blueprint Medicines Corporation | $71.14 | 2024 | Ayvakit |
| Idorsia Pharmaceuticals US INC | $67.57 | 2023-2024 | Quviviq |
| Esperion Therapeutics, INC. | $67.18 | 2022-2024 | Nexletol |
| Biohaven Pharmaceuticals, INC. | $64.37 | 2021 | |
| Merck Sharp & Dohme LLC | $63.42 | 2019-2023 | Steglatro, Belsomra |
| Eisai INC. | $59.70 | 2020-2021 | |
| Boston Scientific Corporation | $39.83 | 2019-2020 | |
| Redhill Biopharma INC. | $34.66 | 2022 | |
| Lundbeck LLC | $32.58 | 2024 | Rexulti |
| Axonics, INC. | $28.33 | 2024 | Axonics |
| Averitas Pharma INC. | $27.65 | 2025 | Qutenza |
| Radius Health, INC. | $27.02 | 2019 | |
| Nevro Corp. | $25.43 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $24.28 | 2023 | Trintellix |
| Alk-Abello, INC | $23.88 | 2024 | Grastek, Odactra, Ragwitek |
| Avanir Pharmaceuticals, INC. | $21.74 | 2021 | |
| Terumo Medical Corporation | $21.42 | 2019 | |
| Halozyme INC | $20.82 | 2023 | |
| Sanofi Pasteur INC. | $19.60 | 2025 | |
| Companion Medical, INC. | $19.47 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $19.46 | 2021 | |
| Bausch Health US, LLC | $18.95 | 2022 | |
| Corcept Therapeutics | $18.12 | 2025 | Korlym |
| Aytu Biopharma, INC. | $17.96 | 2019 | |
| Scynexis, INC. | $17.89 | 2022 | |
| Vivus LLC | $16.76 | 2020 | |
| Intra-Sana Laboratories | $16.35 | 2025 | Reltone 400 Mg, Glycate, Reltone 200 Mg |
| Biohaven Pharmaceutical Holding Company LTD. | $15.92 | 2022 | |
| Amarin Pharma, INC. | $14.43 | 2019 | |
| Arbor Pharmaceuticals, INC. | $14.05 | 2021 | |
| Horizon Therapeutics Plc | $13.95 | 2020 | |
| Acerus Pharmaceuticals Corporation | $12.27 | 2022 | |
| Ibsa Pharma INC. | $11.72 | 2022 | |
| Almatica Pharma LLC | $11.28 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Victor Nguyen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.